Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Diagnostic test for early detection of pancreatic cancer

Reference number
Coordinator RECCAN AB (publ)
Funding from Vinnova SEK 2 999 000
Project duration April 2024 - March 2026
Status Ongoing
Venture Swelife - Collaboration project for better health
Call Swelife - Collaborative projects for better health autumn 2023

Purpose and goal

** Denna text är maskinöversatt ** The purpose of Reccan´s project is to conduct clinical studies to collect data and insights about Reccan Immunoassay, a blood test for early detection of pancreatic cancer in at-risk patients. This is with the goal of being able to offer healthcare a simple test that can detect cancer at an early stage when it can be cured.

Expected effects and result

** Denna text är maskinöversatt ** The clinical activities planned in the project will provide data and insights that will support the inclusion of the test in treatment guidelines and to reach cost coverage for the test in healthcare in Europe. The overall goal is to increase survival for people with pancreatic cancer by offering a test that can detect the cancer at an early stage, which is currently lacking on the market.

Planned approach and implementation

** Denna text är maskinöversatt ** The project will be carried out together with an external CRO to produce the necessary documents and conduct the study.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 22 April 2024

Reference number 2023-03884